Stanford Cancer Institute
Genitourinary

Bladder

Metastatic Disease

- Allows Mixed Histology Post Platinum

  BLDR0026
  Dose Escalation & Expansion
  Enfortumab Vedotin +/- Pembrolizumab
  &/or Chemo in Local/Ad/Max Urothelial Cancer
  PI: Srinivas
  Seattle Genetics

- First Line Therapy

  BLDR0026
  Phase III Enfortumab Vedotin in Combo w/ Pembrolizumab +/- Chemo vs Chemo Alone in Urothelial Cancer
  PI: Srinivas
  Pending

- Cisplatin Ineligible

- Cisplatin Eligible

  BLDR0035
  Phase II/III
  Multiple Immunotherapy Based Tx Combos in Locally Advanced / Metastatic Urothelial Carcinoma
  PI: Shah
  Pending

Prior Tx with Platinum

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu